NADAC acquisition cost data for TYMLOS 80 MCG DOSE PEN INJECTR. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 70539000101 | $1,413.23 | 2022-01-01 | Rx |
| 70539000102 | $1,413.23 | 2022-01-01 | Rx |
| 70539000101 | $1,413.23 | 2022-01-01 | Rx |
| 70539000102 | $1,413.23 | 2022-01-01 | Rx |
| 70539000101 | $1,413.23 | 2022-01-01 | Rx |
| 70539000102 | $1,413.23 | 2022-01-01 | Rx |
| 70539000101 | $1,413.23 | 2022-01-01 | Rx |
| 70539000102 | $1,413.23 | 2022-01-01 | Rx |
| 70539000101 | $1,413.23 | 2022-01-01 | Rx |
| 70539000102 | $1,413.23 | 2022-01-01 | Rx |
Generic: Abaloparatide | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $109.8M | 53,449 | 11,120 | $1,187.83 |
| 2020 | $132.8M | 60,036 | 11,704 | $1,281.47 |
| 2021 | $137.8M | 58,817 | 11,638 | $1,403.71 |
| 2022 | $156.7M | 60,207 | 11,168 | $1,528.00 |
| 2023 | $197.6M | 69,151 | 12,979 | $1,690.13 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Texas | $24.4M | 8,552 | 1,687 |
| California | $24.3M | 8,302 | 1,615 |
| New York | $13.6M | 4,479 | 909 |
| Florida | $13.3M | 4,604 | 872 |
| Pennsylvania | $12.5M | 4,526 | 789 |
| North Carolina | $6.7M | 2,399 | 454 |
| Colorado | $6.4M | 2,310 | 441 |
| Massachusetts | $6.1M | 2,140 | 368 |
| Michigan | $5.5M | 1,949 | 368 |
| Tennessee | $4.9M | 1,704 | 315 |
| Missouri | $4.9M | 1,728 | 323 |
| Indiana | $4.5M | 1,592 | 293 |
| Georgia | $4.4M | 1,476 | 313 |
| Illinois | $4.3M | 1,454 | 274 |
| Ohio | $4.2M | 1,356 | 254 |
| Idaho | $4.1M | 1,560 | 234 |
| Minnesota | $3.4M | 1,206 | 212 |
| Washington | $3.3M | 1,182 | 211 |
| New Jersey | $3.3M | 1,135 | 204 |
| Louisiana | $3.1M | 1,142 | 199 |
| Arizona | $3.0M | 1,042 | 198 |
| Wisconsin | $2.9M | 1,059 | 173 |
| Maryland | $2.8M | 924 | 175 |
| Alabama | $2.6M | 969 | 197 |
| South Carolina | $2.4M | 853 | 188 |
| Connecticut | $2.3M | 728 | 156 |
| Kentucky | $2.2M | 808 | 182 |
| Virginia | $2.1M | 723 | 143 |
| New Mexico | $1.8M | 648 | 113 |
| Oregon | $1.7M | 645 | 102 |
| Puerto Rico | $1.6M | 621 | 118 |
| Utah | $1.6M | 547 | 115 |
| Mississippi | $1.5M | 590 | 95 |
| Oklahoma | $1.4M | 510 | 111 |
| Arkansas | $1.4M | 474 | 90 |
| Nevada | $1.3M | 449 | 100 |
| Iowa | $1.1M | 403 | 69 |
| Kansas | $947.8K | 327 | 69 |
| Delaware | $797.3K | 249 | 56 |
| South Dakota | $732.4K | 265 | 47 |
| New Hampshire | $677.0K | 226 | 44 |
| Hawaii | $546.7K | 201 | 40 |
| Alaska | $485.2K | 154 | 30 |
| District of Columbia | $439.8K | 139 | 27 |
| Maine | $434.7K | 143 | 27 |
| West Virginia | $406.3K | 145 | 36 |
| Rhode Island | $310.3K | 116 | 23 |
| Nebraska | $305.9K | 111 | 20 |
| North Dakota | $268.5K | 91 | 20 |
| Vermont | $231.3K | 74 | 12 |
| Montana | $215.8K | 73 | 14 |
| Wyoming | $25.8K | 11 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.